In vitro analysis revealed sulbactam-durlobactam efficacy against carbapenem-resistant Acinetobacter baumannii isolates, suggesting new treatment options.
Cefiderocol and sulbactam-durlobactam exhibited strong in vitro activity against carbapenem-resistant A. baumannii isolates from a single University Hospital and may represent valuable treatment options for patients with limited therapeutic alternatives.
No takes yet. Share an insight, caveat, or question.
Palavecino et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: